Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722987 | 0.78 | GAA (0.31) | — | |
| SCHEMBL10201105 | 0.70 | STIM1 (0.83) | STIM1ORAI1NPC1RAB9A | |
| SCHEMBL29642099 | 0.69 | STIM1 (0.71) | STIM1ORAI1NPC1RAB9A | |
| SCHEMBL721821 | 0.69 | STIM1 (0.71) | STIM1ORAI1NPC1RAB9A | |
| SCHEMBL1701216 | 0.68 | STIM1 (0.45) | STIM1ORAI1NPC1RAB9AMAPK14 | |
| SCHEMBL724067 | 0.68 | L3MBTL1 (0.30) | — | |
| SCHEMBL724532 | 0.67 | GAA (0.31) | — | |
| SCHEMBL722534 | 0.66 | BRD4 (0.33) | — | |
| SCHEMBL724411 | 0.65 | STIM1 (0.48) | STIM1ORAI1NPC1RAB9ARIPK2 | |
| SCHEMBL10201083 | 0.64 | STIM1 (0.75) | STIM1ORAI1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.